Dr Apostolos Zarros, physician, MRes, PhD, PhD (born 1983, Greece) is the Director of the Glasgow-based Pharmacological Research Observatory, and an Honorary Research Fellow at the Institute of Cancer Sciences of the University of Glasgow. Ηe has undertaken undergraduate, postgraduate and postdoctoral research focusing on the development and assessment of experimental simulation approaches to brain diseases.

Dr. William Cho is a Chartered Scientist granted by the Science Council (UK) and a fellow member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Besides, Dr. Cho being a Guest Professor in several Universities, he is also a registered Chinese medicine practitioner. He has published over 300 papers and book chapters covering cancer biomarkers, proteomics and microRNAs. His main research interests involve focusing on cancer studies by utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication.

Dr. Miller received his Ph.D. in 1979 from the University of Texas, did a postdoc in dopamine electrophysiology at UT Southwestern until 1982, followed by a second postdoc in circadian neurobiology at UC Riverside and UC Davis until 1987. From 1982-1987 he also served as a NASA space shuttle project director. Dr. Miller was a research associate in the Stanford Biology Department from 1987-1994 and the Director of Neurochemistry in the Stanford-Upjohn Center for the Study of Sleep and Circadian Rhythms. He was a faculty member in the Department of Pharmacology, Texas Tech Health Sciences Center from 1994 until 2000.From 2000 to 2013 he was an associate professor in the Department of Cell and Neurobiology at the Keck School of Medicine at USC. In March 2013 he accepted a position as Chair of Pharmacology at the American University of the Caribbean School of Medicine where he continues to work.

Suowen Xu, Ph.D., is a natural product pharmacologist. Dr. Xu received his Ph.D. did postdoc studies in biochemistry at NHLBI/NIH, followed by a second postdoc in vascular biology at University of Rochester. Currently, Dr. Xu is Research Assistant Professor of Medicine at University of Rochester. He is a principal investigator interested in identifying novel therapeutic targets and molecular interventions of cardiovascular diseases. He was also an adjunct faculty member (Associate Professor) in the School of Pharmacy, The University of Queensland. He is an editorial board member of 4 journals and serves as reviewers for over 50 journals.

Nelson S. Yee, M.D., Ph.D., F.A.C.P. R.Ph. is the Team Leader of Gastrointestinal Oncology at Penn State Cancer Institute. Dr. Yee received undergraduate education at Massachusetts College of Pharmacy. He then pursued medical education and graduate research training at Cornell University Medical College and Memorial Sloan-Kettering Cancer Center. At Hospital of the University of Pennsylvania, he underwent clinical training in Internal Medicine, Hematology, and Medical Oncology. Currently, Dr. Yee is Associate Professor of Medicine at Pennsylvania State University. He is the principal investigator of clinical studies for new treatment as well as cancer biomarkers and targets in cancer of digestive organs.

Jianxun Ding is a Professor at Changchun Institute of Applied Chemistry (CIAC), Chinese Academy of Sciences (CAS). He received his B.S. degree from University of Science and Technology of China in 2007 and obtained his Ph.D. degree from CIAC, CAS, under the supervision of Prof. Xuesi Chen in 2013. During 2017 − 2019, he worked with Prof. Omid C. Farokhzad and Prof. Jinjun Shi from Harvard Medical School as a Postdoctoral Research Fellow. He has published more than 150 articles and applied for over 70 Chinese patents. His research focuses on polymer chemistry, controlled drug delivery, immunotherapy, and regenerative medicine.

Professor Akira Sugawara belongs to the Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan. He graduated from Tohoku University School of Medicine on 1987 (M.D.), and got Ph.D. on 1991 from Tohoku University Graduate School of Medicine. He performed Postdoctoral Fellowship in William Chin’s laboratory at the Women’s Hospital/Harvard Medical School in Boston from 1991 to 1994. His major is general internal medicine, endocrinology and metabolism and hypertension and nephrology. His research interest is 1) molecular biology of nuclear hormone receptors, 2) etiology of high blood pressure, 3) pathophysiology of diabetic nephropathy, 4) gene regulation of aldosterone synthase, and 5) epigenetics of hypertension and diabetes mellitus.

Prof. Dr. Esra Küpeli Akkol got her Bachelor of Science degree in Faculty of Pharmacy, Gazi University, Turkey and obtained her Ph.D. degree in Pharmacognosy from the University of Gazi. Currently, she is a Professor in the Gazi University, Faculty of Pharmacy, Department of Pharmacognosy. She served in many capacities in her field including service on several editorial boards and numerous review committees for journals such as Journal of Ethnopharmacology, Journal of Pharmacy Sciences, The Internet Journal of HerbalandPlantMedicine, International Journal of Genuine Traditional Medicine, Advances in Pharmacological Sciences, Evidence Based Complementary Alternative Medicine and The Open Pain Journal. She has conducted 41 projects and 11 thesis in Gazi University. She has 158 published articles in SCI International Journals, 13 articles in National Journals and 10 chapters in International books.

Prof. Bishayee has 25 years of combined experience in pharmaceutical education, research, teaching, and administration. Prof. Bishayee’s primary research interest encompasses cancer biology, cancer therapeutics, and cancer prevention. His laboratory is involved in investigating cancer preventive and therapeutic effects of medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer, including breast and liver cancer, and underlying molecular mechanisms of action. He has published around 200 peer-reviewed original research papers and authoritative review articles, mostly in high-impact journals, 15 book chapters, and around 70 abstracts and delivered more than 30 invited presentations at various national and international scientific meetings.

DR. Mrinal K Ghosh is currently working as Senior Principal Scientist & HOD, Cancer Biology, CSIR-Indian Institute of Chemical Biology. He has fulfilled his MS and PhD in Biochemistry, University of Calcutta and Post-Doctoral training during 1997-2003 at the Lerner Research Institute (LRI), Dept. of Molecular Biology, Cleveland Clinic Foundation, USA. Later on, he joined as staff at Dept. of Cancer Biology, Cleveland Clinic Foundation, USA and worked till 2005. Since 2007 at CSIR-IICB he has been actively engaged in cancer research. At present he is in the reviewer/editorial committee of many Journals as well as International [(World Cancer Research, UK & Health Research Board (HBR), Ireland], and National Research Grants. He has many high impact peer-reviewed publications such as Molecular Cell-2003, EMBO J- 2001, JCB- 2000, Oncogene- 2005, 2013, 2015 & 2017, J Virology- 2001 & 2010, Oncotarget-2017, Cellular Signaling-2014 & 2016, Cellular Oncology-2015 JBC-2012a&b etc.

Dr. Khan is the full Professor at the Department of Pharmacy, Abdul Wali Khan University Mardan (AWKUM), Pakistan. In 17 years of professional experience, he has significantly contributed to the teaching and training of pharmacy graduate and pharmacy-related services. Dr. Khan remained the member of AWKUM syndicate, executive member of Pharmacy council of Pakistan KP and editorial member of more than 10 journals including Phytomedicine, Food and Chemical toxicology and Metabolic Brain Disease. He is the author of 213 articles including editorial, review, research and four books including one by Elsevier. Moreover, several post- graduate scholars are working under his supervision.

Dr Kannan RR Rengasamy has a proven track record in research towards functional food-based drugs discovery. He has been working in several research positions at reputed international organizations. He is currently an Extraordinary Associate Professor at College of Natural and Agricultural Sciences, North-West University, South Africa. Dr. Rengasamy has good expertise in natural product chemistry and pharmacology, marine natural products and enzyme inhibitors. He has published more than 114 papers in SCI journals and edited several special issues for highly reputed journals in the field of natural product pharmacology. Furthermore, he is active in exploring natural resources for novel enzyme inhibitors which are clinically valuable for the management of various diseases.

Dr. Serkan Yilmaz is serving as Professor, in Ankara University Faculty of Nursind and Institute of Forensic Sciences. He did his Ph.D in Genetics from Gazi University, Turkey. He is an official member of a number of international societies. He received awards from The Scientific and Technological Research Council of Turkey, Gazi University and Ankara University. His research interests are Genetics, Toxicology, Cancer Biology, Molecular Biology. He has more than 30 peer reviewed publications, 2 books. He has many editorial board memberships, and serve as associate editor and editor in many journals.

Dr. Yukio Yoneda is a Professor Emeritus in Kanazawa University, where he worked as a Chairman Professor of Pharmacology from 1999 to 2015. He graduated from Osaka University Faculty of Pharmaceutical Sciences in 1972, and from the Graduate School in 1975. He was then appointed as an Assistant Professor in Kyoto Prefectural University of Medicine and completed his PhD from the same university in 1979. During this appointment as an assistant professor, he worked with Dr. Eugene Roberts, a finder of GABA in the brain, in the City of Hope Research Institute, CA, USA, as a postdoctoral research fellow for 14 months between 1980 and 1981. In 1982, he was promoted to a Senior Assistant Professor in Kyoto Prefectural University of Medicine. He moved to Setsunan University Faculty of Pharmaceutical Sciences as an Associate Professor in 1984, followed by promotion to a full Professor in 1997 and subsequent appointment as a Chairman Professor in Kanazawa University in 1999. He has been teaching Pharmacology in Osaka University after the retirement from Kanazawa University in 2015. He is still active in serving as an Associate Editor in several international reputed journals such as Neurochemistry International and Neurochemical Research, in addition to playing a role as the Editorial Board in other international reputative journals. He has published more than 350 research papers in reputed journals. His research interests have been lying on pharmacological profiling of amino acid signaling in neuronal and non-neuronal cells using molecular biological techniques. As a return of laboratory experimental results to the community, he has made several dietary supplement products enriched of theanine for online sales, which are all expected to be beneficial for the prophylaxis and/or treatment of different brain dysfunctions, besides the sustained bench work with colleagues in domestic and foreign universities.

Dr. Gisele Zapata-Sudo is Full Professor of Cardiovascular Pharmacology at Federal University of Rio de Janeiro, Brazil. She received her medical degree from School of Medicine Souza Marques in 1986 and completed her PhD in Biophysics from Federal University of Rio de Janeiro in 1994, after which she was appointed as an Associate Professor. Dr. Zapata-Sudo has more than 30 years of experience in education, research and supervision of graduate students in the field of cardiology and pharmacology. Her research interests have been focused on the design, development and pharmacological evaluation of new compounds synthesized to act in the cardiovascular system and treat heart diseases.

Dr. Allen is a Professor at the Oregon Institute of Occupational Health Sciences and the Department of Behavioral Neuroscience at the Oregon Health & Science University. He received his Ph.D. in Pharmacology from University of Texas Southwestern Medical Center at Dallas. He has authored more than 75 manuscripts and six reviews. The research in his lab focuses on understanding how neurons in the hypothalamic suprachiasmatic nucleus (SCN) the master circadian oscillator generate circadian timing signals and entrain to the environmental light-dark cycle. We use single-cell electrophysiological recordings, long-term measurements of behavior, and long-term live cell imaging methods to study the signaling pathways in the neural network of SCN neurons and how those contribute to the synchronization of individual SCN oscillators.

Dr. Yasu-Taka Azuma is presently serving as an Associate Professor at Osaka Prefecture University and as a Secretary-General at The institute of Prophylactic Pharmacology, Japan. He completed his M.S in 1996 from Setsunan University Graduate School of Pharmaceutical Sciences. He further obtained a Ph.D. from Osaka Dental University in 2001. His research interests include Interleukin-19; Inflammatory bowel disease; Mucosal Immunology; Inflammation; Fibrosis; NASH & Hepatitis; Pancreatitis; Transgenic Mice; Knockout Mice. He has contributed his valuable publications in different scientific journals.

Davide Barreca is an Associate Professor of biochemistry at the University of Messina. He is specialized in enzyme modulation by natural compounds, inhibition of protein aggregation and activation of signal apoptotic cascade. Most of his research projects concentrate on separation and identification of unknown flavonoids, structural-activity elucidation, and biochemical analysis of their health promoting or cytotoxicity properties on cells culture. He is author of over 90 papers in peer-reviewed journals, 30 chapters in books, and 70 conference proceedings and reviewer of over 40 international scientific journals.

Dr. Blanton obtained a doctorate (Ph.D.) in Biology/Biochemistry from the University of California, Santa Cruz, followed by postdoctoral training at Washington University School of Medicine, St. Louis, MO and at Harvard Medical School, Boston, MA. Currently Dr. Blanton is a Professor and Vice-Chair in the Department of Pharmacology and Neuroscience at Texas Tech University Health Sciences Center, Lubbock, TX. Dr. Blanton is also a Senior Associate Dean in the Graduate School of Biomedical Sciences and director of the MD/PhD Program and the Center for Membrane Protein Research. Dr. Blanton’s research focus is on the structure/function of ligand-gated ion channels, in particular neuronal nicotinic acetylcholine receptors (nAChRs).

Dr. Tracey Bradshaw joined the Experimental Cancer Chemotherapy group within the Cancer Research Laboratories, University of Nottingham in 1993. Now an assistant professor within the School of Pharmacy, her specific research interests lie in the discovery and development of novel anticancer therapeutics embracing NCEs, natural products, nano-medicines and gelators. Research activities within the field of cancer pharmacology include determination of anticancer activity and elucidation of molecular targets and mechanisms of action of novel preclinical antitumour agents. Such research led to clinical evaluation of Phortress and >90 publications. She is a member of the Drug Discovery Group, PAMM, EORTC and EACR.

Dr. Buolamwini obtained a doctorate (Ph.D.) in Pharmaceutical Sciences from the University of Alberta, Canada. Currently Dr. Buolamwini a Professor in the Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science. He has published more than 70 scientific publications, edited two books, and is a named inventor of 4 issued U.S patents. Dr. Buolamwini was the founding Editor-in-Chief (2001-2013) of Current Cancer Drug Targets, published by Bentham Science Publishers.

Félix Carvalho, PharmD, PhD, is Full Professor of Toxicology, at the Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy at University of Porto (FFUP), and researcher of the Research Unit on Applied Molecular Biosciences (UCIBIO), Portugal. He is presently the Vice-President of the Portuguese Society of Pharmacology, Vice-director of UCIBIO and Secretary-General of EUROTOX. During the past 27 years, Félix Carvalho has published over 315 scientific articles / book chapters and is co-editor of two Books in the area of Toxicology.

Dr. Guoxun Chen obtained his BS and MS degrees in the Department of Virology and Molecular Biology at Wuhan University, Wuhan, China. He completed his Ph.D degree in the Department of Biochemistry and Molecular Biology at the University of Texas Southwestern Medical Center at Dallas in 2001. After that, Dr. Chen entered the Department of Molecular Genetics at the University of Texas Southwestern Medical Center for the postdoctoral training. In 2006, he became a faculty member in the Department of Nutrition at the University of Tennessee at Knoxville. Now, he is a tenured associated professor at the University of Tennessee. Since the establishment of his independent research lab in 2006, Dr. Chen has focused on the roles of vitamin A in the development of metabolic diseases such as obesity and diabetes, and the regulation of glucose and lipid homeostasis.

Dr. Chow currently is a Professor and Vice Chair in the Department of Molecular and Medical Pharmacology, UCLA School of Medicine. Dr. Chow¹s research is on the molecular mechanism of retroviral DNA integration, a process essential for reproduction of human immunodeficiency virus (HIV) and other retroviruses. Dr. Chow has developed simple in vitro assays for understanding the mechanism of the integration process and screening for new anti-retroviral drugs. Dr. Chow¹s laboratory is also interested in determining the functional role of HIV integrase during reverse transcription and particle assembly, as well as improving retrovirus-based vectors as a vehicle for gene delivery in mammalian cells.

Dr. Civelli is Professor and Chair of the Department of Pharmacology at University of California, Irvine. He holds the Eric L and Lila D Nelson Chair of Neuropharmacology. Previously he was vice president at F. Hoffmann-La Roche, Basel. He is a recognized leader in the field of neuropsychopharmacology. He was the first to clone the D2 dopamine receptor and discovered the diversity of the dopamine receptors, in particular the D4 receptor. He spearheaded reverse pharmacology and used it to discover the first new neuropeptide identified by this approach, nociceptin/orphanin FQ and later neuropeptide S. He discovered the receptors for melanin concentrating hormone and for urotensin II. His primary interest is the study of neuropsychiatric disorders, in particular schizophrenia. He has authored more than 200 manuscripts and holds 30 patents.

Ricardo Jorge Dinis-Oliveira completed a PhD degree in Toxicology in the University of Porto. By Rector Dispatch awarded the European PhD. He holds 2 Post-Doc in Toxicology and Pharmacology, and Habilitation (Aggregation) in Forensic Sciences by the Faculty of Medicine, University of Porto. He published more than 145 papers, 35 book chapters, edited 4 books and 4 patents. He is Director of the Course in Forensic Laboratorial Sciences, Course in Biomedical Sciences and of the Master in Forensic Sciences and Laboratory Techniques of University Institute of Health Sciences. He is the president elect of the Portuguese Association of Forensic Sciences. His current h-index is 26 according to SCOPUS.

The research activity of Dr. Dossena is focused on the characterization of ion transport molecules as novel drug targets, including the protein ICln, the sodium-chloride co-transporter NCC, the cystic fibrosis transmembrane chloride conductance regulator chloride channel CFTR, and molecules involved in hereditary deafness (GJB2, GJB6, SLC26A4, transcription factors such as FOXI1 and POU3F4). Dr. Dossena is author of more than 50 scientific papers published in high impact factor journals, (including PNAS, JBC, Nature Review Drug Discovery, Molecular Medicine, Scientific Reports) and is recipient of numerous prices for her research activity. She participates in international congresses as a speaker or chair on a regular basis and is engaged in peer-reviewing activity for several international scientific journals.

Scott T. Eblen, PhD, earned a BS in Biology from the University of Kentucky and a PhD from Vanderbilt University, performing his dissertation research both at Vanderbilt and the Mayo Clinic. He did postdoctoral work at the University of Virginia in the area of signal transduction by protein kinases. He is currently an Associate Professor of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina in Charleston, SC. His lab studies signal transduction by protein kinases, E3 ubiquitin ligases, and mRNA splicing in the context of cancer and molecular mechanisms of drug resistance.

Dr. Enomoto is presently a Senior Lecturer in Kobe Gakuin University. She graduated from Setsunan University Faculty of Pharmaceutical Sciences in 1990, and from the Graduate School in 1992. She was then appointed as a Research Assistant in Kobe Gakuin University in 1993. Dr. Enomoto received her Ph.D. from Osaka University in 2003. She uses model mice and cell cultures to study the role of microglia in brain dysfunction. Recently, Dr. Enomoto is interested in autism and delirium.

Dr. Fishel obtained her Ph.D. degree (in 2001) in Biochemistry and Molecular Biology from Indiana University School of Medicine, Indianapolis, IN, USA. Dr. Fishel is currently Assistant Professor (Pediatrics, Hematology/Oncology) at Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine. Her research interests have been in exploring rationale molecular targets in difficult-to-treat, refractive cancers, such as pancreatic cancer as well as glioblastoma and pediatric leukemia. Dr. Fishel, as an author/co-author, has published more than 50 articles in various journals, having over 1,655 total citations.

Dr. Avila obtained a PhD in Biophysics at the Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav, IPN), where he is currently an Associate Professor (Biochemistry Department). His lab focuses on investigating the structure pharmacology and regulation of ion channels in striated muscle. Thus far, Dr. Avila has published 34 peer-reviewed research articles.

Dr. Dwight German received his Ph.D. training in neuroscience at the University of Oklahoma Health Sciences Center and went on to do post-doctoral work in the Department of Physiology & Biophysics and the Regional Primate Research Center at the University of Washington. He is currently a Professor in the Department of Psychiatry at the University of Texas Southwestern Medical Center. His research focuses on neurodegenerative and neurodevelopmental disorders using both post-mortem human tissues and animal models. His research also focuses on developing blood biomarkers for neurodegenerative/neurodevelopmental disorders.

The research in my laboratory for the past 30 years has been directed towards the areas of experimental chemotherapy and radiotherapy in cancer, with a primary focus on breast cancer and lung cancer. Work has been largely focused on sensitization of lung cancer and breast cancer to radiotherapy and chemotherapy. These efforts have also served to define autophagy and senescence (rather than apoptosis) as primary responses to both chemotherapy and radiotherapy in solid tumor cell models. We have established the existence of cytostatic and cytotoxic functions of autophagy in lung cancer cells and breast cancer cells while recent work has also identified a non-protective form of autophagy that is critical to understanding why efforts towards chemosensitization and radiosensitization via autophagy inhibition may prove to be particularly challenging in the absence of appropriate predictive biomarkers. Current work is focused on approaches for establishing the reversibility of senescence both in cell culture and tumor bearing animal models, with the longer term goal of understanding the role of senescence in sensitivity (or refractoriness) to therapy in breast and lung cancer.

Dr. Wael M Abdel-Rahman (Hassan); MBBCH, MSc (Pathology), PhD (Molecular Pathology) is the coordinator of the MSc/PhD program in Molecular Medicine, College of Medicine and Associate Professor at the College of Health Sciences, University of Sharjah. He is one of the inaugurating researchers of the Sharjah Institute of Medical Research. He is the chair of the College Research Committee and ex-member of the University Postgraduate Studies Council. He is a board member of many scientific journals and conferences and acted as a referee in many awards and grants.

Chaunshu Huang is a Professor of Department of Environmental Medicine and Biochemistry and Molecular Pharmacology and Urology, and Deputy Director of Nelson Institute of Environmental medicine, New York University School of Medicine. Dr. Huang published more than 280 research papers with total citation over 11,200. Chuanshu’s major research addresses fundamental questions concerning the responses of mammalian cells to environmental carcinogens at the levels of protein kinases, transcription factors and their target genes, as well as protein modification both in vitro and in vivo. His research also includes elucidation of tumor invasion and metastasis, as well as screening and identifying novel anti-cancer drugs and the molecular mechanisms underlying their anti-cancer effect.

Peng Huang, M.D., Ph.D., is a professor at the University of Texas MD Anderson Cancer Center, Houston, Texas. He received his medical degree at Sun Yat-sen University School of Medicine and his PhD degree from the University of Texas Graduate School of Biomedical Sciences at Houston. Dr. Huang’s research interests are in the areas of cancer metabolism, ROS/redox biology, and anticancer agents. In particular, his laboratory investigates the mechanistic links between oncogentic signals, mitochondrial alterations, and changes in cellular metabolism and drug sensitivity. He has over 160 publications including high-impact articles that are frequently cited. Prof. Huang is currently Associate Editor of Molecular Cancer and a member of editorial boards of multiple scientific journals.

Dr. Imran Kazmi is currently working as a Principal & Professor of Pharmacy in Shine Abdur Razzaque Institute of Health Education & Research Centre, Ranchi, India. Previously he worked as an Associate Professor in Glocal Univrsity, Saharanpur, India. He completed his PhD from Pacific University and M.Pharm from Jamia Hamdard, New Delhi. His key area of research is pharmacological evaluation and establishment of mechanism of action of novel isolated phytoconstituents and synthetic drugs. He has more than 60 papers in different referred journal with cumulative Impact Factor above 100. He wrote more than 14 books/chapters with different publishing groups. He also has one Indian Patent on novel molecule isolated from Lantana camara medicinal plant.

Dr. Kelley is the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor, Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Director, Program in Pediatric Molecular Oncology & Experimental Therapeutics, Indiana University School of Medicine. He is also the Associate Director, Herman B Wells Center and the Associate Director for Basic Science at the IU Simon Cancer Center. Dr. Kelley has a PhD from LSU and postdoctorate at The Rockefeller University. He has published over 170 peer-reviewed articles, 30 reviews/book chapters and has 11 patents. He also edited both editions in DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications.

Dr. Sunil Kumar received his Master degree in Biotechnology from the Devi Ahilya University, Indore, (India) in 2006 and his PhD in Biotechnology from Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India in 2011. He is currently an Associate Professor at the Shri Ramswaroop Memorial University, Barabanki, Uttar Pradesh, India. His research interests include genetic engineering, molecular biology, medical microbiology particularly focused on molecular characterization of bacterial biofilm and drug development and inflammatory bowel diseases. Dr. Kumar has authored more than 40 peer-reviewed articles, Ten book chapters and edited four books for springer, Elsevier and Bentham. His works have been published in several leading journals including American Journal of Clinical Nutrition, Journal of Gastroenterology Hepatology, Digestive Diseases and Science, Clinical Therapeutics, Microbial Pathogenesis, Journal of Neurogastroenterology and Motility, Biomedicine and Pharmacotherapy, etc.

Dr. Vinod Kumar obtained his Ph.D. degree (in 2007) in Organic Chemistry from Guru Nanak Dev University (GNDU), Amritsar, India. Presently, Dr. Kumar is an Assistant Professor, in the Centre for Chemical and Pharmaceutical Sciences, at Central University of Punjab, Bathinda, India. His skills and expertise mainly lie in the subject areas/fields of Organic Synthesis, Medicinal Chemistry, Natural Products Chemistry, and Green Chemistry. Dr. Kumar, as an author / co-author, has published over 20 manuscripts in various journals.

Dr. Lariccia received his Ph.D. degree in Neuroscience from the University “Federico II”, Naples, Italy. He joined as Assistant Professor of Pharmacology the University “Politecnica delle Marche”, following completion of his studies on the regulation of Na-transporters by surface membrane turnover with Dr. Donald W. Hilgemann at the UTSouthwester, Dallas. Dr. Lariccia use electrical and optical methods to investigate the regulatory processes that govern the activity of Na-transporters, recently with a focus on the functional interaction between NCXs and glutamate transporters from EAAT family.

Sichuan University, China (BS, 1990), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (MS, 1993; Ph.D. 1996), NIH (Post Doct. 1997-2000), Shanghai Institute of Materia Medica, Chinese Academy of Sciences (full professor, 2001-2017). From April 2017, Dr. Long joined Soochow University Medical College in Suzhou, China as the distinguished professor and vice dean. She has published more than more than 90 scientific publications and is a named inventor of 20 issued Chinese patents and 2 U.S patents. Research Interests: (1) Medicinal chemical biology, and (2) Design, synthesis and structure-function relationship study of antivirals and antitumor agents, and (3) green chemistry construction of privileged structure and natural product fragment-based focused library.

Dr. Lu received his PhD degree in Shanghai Institute of Meteria Medica, Chinese Academy of Sciences in 2009. Since 2012, he joined University of Macau as an Assistant Professor and promoted to be Associate Professor in 2018. Dr. Lu mainly focuses on screening of natural compounds with anti-cancer potential and exploration of the molecular mechanisms. He is also interested in studying the new targets and strategies for cancer therapy. To present, Dr. Lu has published more than 140 scientific papers in the professional journals.

Dr. Marson is a researcher acting in the multidisciplinary team of Asthma and Cystic Fibrosis. responsible for Medical Genetics studies, including the studies of Asthma prevalence and severity, and in Cystic Fibrosis, with studies on CFTR mutations screening, cystic fibrosis diagnosis and clinical modulation by modifier genes. Dr. Marson is also responsible for the statistical analysis of: (i) modifier genes and severity of respiratory diseases, (ii) methods/tools for Cystic Fibrosis diagnosis, (iii) epidemiological analysis regarding respiratory diseases, (iv) risk factor for cancer, (v) bacteria modulation on clinical severity of Cystic Fibrosis, (vi) and in the use of Mutifactor Dimensionality Reduction tool. More than ninety studies have been published in the area of genetics and respiratory diseases in the last four years. Actually, Dr. Marson acts as a biostatistician in the Brazilian Study Groups for Chronic Obstructive Lung Disease and Medical Genetics Group.

Dr. Nakamichi is a Professor in the Faculty of Pharmacy at Takasaki University of Health and Welfare. He received his Ph.D. in Pharmaceutical Science from Kanazawa University. He was appointed as an Assistant Professor and then promoted to an Associate Professor in the Faculty of Pharmacy at Kanazawa University. He has published more than 90 research papers in reputed journals. His research interest is on the optimization of drug therapy for central nervous system diseases.

John L. Nitiss PhD is a professor of Pharmacology and Assistant Dean for Research at the University of Illinois College of Pharmacy. Prior to joining the University of Illinois in 2011, Dr. Nitiss was in the Molecular Pharmacology Department at St. Jude Children’s Research Hospital (1994-2011) and the Department of Pediatrics and Biochemistry at the University of Southern California (1989-1994). He received his PhD in 1986 from the Illinois Institute of Technology in 1986, and carried out postdoctoral work under the direction of James Wang at Harvard University (1987-1989). His laboratory works on DNA topoisomerases as targets of anti-cancer drugs and mechanisms of DNA repair.

Dr. Steven Christopher O’Reilly, Ph.D., is currently a Senior Lecturer of Immunology in the Faculty of Health and Life Sciences, at Northumbria University, UK. His skills and expertise mainly lie in the subject areas of Rheumatology, Immunology, Clinical Immunology, Internal Medicine (General Medicine), Neurology, Diabetology, Pediatrics, etc. Dr. O’Reilly has been awarded funding from the likes of Rosetrees Trust (August 2016-2017), JGW Patterson Foundation (September 2016-2017) and North East Skin Research Fund (2018) for different researches.

Dr. Masato Ogura is presently serving as a lecturer at Fukushima Medical University School of Medicine, Japan. He completed his M.S in 2006 from Kanazawa University Graduate School of Natural Science and Technology. He further obtained a PhD. from Kanazawa University Graduate School of Natural Science and Technology in 2009. His research interests include Neuronal Cell Death; Glial Activation; Neurodegeneration; Pharmacology; Inflammation; Immunology; Cell Signaling; Small Molecular; Proteome; Transgenic Mice.

Hirotaka Oikawa graduated from the Faculty of Pharmaceutical Science at Hokuriku University in 2003 and the Graduate School of Natural Science and Technology at Kanazawa University in 2008. He was affiliated with the Department of Pediatrics, Saint Louis University as a research fellow from 2006 to 2010 and as a postdoctoral fellow in 2010. He was also affiliated with Singapore Institute for Clinical Sciences as a postdoctoral fellow from 2010 to 2014. He was appointed as a Research Associate in the Faculty of Pharmaceutical Sciences at Suzuka University of Medical Science from 2014 to 2016 and as an Assistant Professor since 2016.

Prof. Pedro F. Oliveira was conferred his Biochemistry degree in 1996 at University of Porto. In 2004 he was conferred a PhD degree in Biomedical Sciences at the Institute for Biomedical Sciences Abel Salazar (ICBAS), University of Porto, where he did a Post-Doctorate on Reproductive Biology. Presently, he is a Principal Researcher at i3S – Instituto de Investigação e Inovação em Saúde and a Professor at ICBAS, University of Porto. His main research interests are Biology of Reproduction, Urology, Andrology and Biochemistry, with a particular emphasis on the metabolic modulation of spermatogenesis. His contribution to these research fields has been recognized with the attainment of several research grants and with the invitation to publish in a number of leading journals.

Dr. Hany A. Omar received his Ph.D. degree in 2010 from the Ohio State University, Columbus, Ohio, USA. Dr. Omar is currently an Associate Professor of Molecular Pharmacology and Therapeutics in the Department of Pharmacy Practice and Pharmacotherapeutics (College of Pharmacy) at University of Sharjah, UAE. He is an author/co-author of over 70 scientific articles. His research focuses on the molecular mechanisms of anticancer drugs with a special focus on the treatment of hepatocellular carcinoma, colon, breast and prostate cancers. Furthermore, his research activities include the determination of anticancer activity and elucidation of molecular targets, safety, and mechanisms of action of novel preclinical anti-tumor agents.

Dr. Pelicano obtained a doctorate (Ph.D.) in Chemistry and biochemistry from the University of Montpellier II, France. Currently Dr. Pelicano is an instructor at MD Anderson cancer center in Houston. Dr. Pelicano’s research focuses on cancer metabolism, oxidative stress, anticancer agents, and novel therapeutic strategies. Dr. Pelicano has published more than 40 peer-reviewed research articles.

Dr. Balakumar Pitchai is working as a Professor of Pharmacology at Pannai College of Pharmacy, Tamilnadu, India. Previously, he was a Professor of Pharmacology at the College of Pharmacy, King Khalid University, Saudi Arabia, and Senior Associate Professor and Head of Pharmacology Unit at the Faculty of Pharmacy, AIMST University, Bedong, Malaysia. He obtained M.Pharm and Ph.D (awarded in 2007) degrees in Pharmacology specialized in Cardiovascular Pharmacology from the Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, Punjab, India. He published more than 110 scientific papers in the areas of Cardiovascular, Renal, Diabetic and Metabolic Pharmacology, among others. His scientific papers have been cited more than 2910 times (SCOPUS), and his ‘H Index’ is 32 (SCOPUS). He received “Naranjan S. Dhalla Young Scientist Award” in 2007 from the International Society of Heart Research (ISHR) and International Academy of Cardiovascular Sciences (IACS). His name is listed among the World Ranking of Top 2% Scientists, under the Field: Pharmacology & Pharmacy, based on an independent study done by Stanford University scientists (Year 2020).

Dr. Plasencia obtained a doctorate (Ph.D.) in Medicine and surgery from the University Autonoma of Barcelona (Barcelona, Spain). Dr. Plasencia also holds an Executive Masters in Biotechnology from Genoma España and is currently finalizing the Executive Master in Business Administration from EAE business school (Barcelona). Currently Dr. Plasencia is co-founder and chief executive officer of the small biotech Applied Research using Omic Sciences (Aromics S.L.) and co-founder and chairman of the board of Aesis Therapeutics (Italy) and Acceleromics (Spain). All three biopharmaceutical companies are devoted to the development of novel antitumor and antiviral agents. She has scientific publications in international journals and currently acts as European expert for European Commision R&D programs.

Dr Philippe Pourquier obtained a doctorate (Ph.D.) in Biochemistry and Molecular Biology from the University of Bordeaux, France. Dr Pourquier also holds a Pharmacy Doctorate from the same University. Dr Pourquier is currently a Research Director at the french National Institute of Health and Medical Research (INSERM) in the research unit U1194 in Montpellier, France. Dr Pourquier acquired a solid experience in the field of drug resistance to anticancer agents, in particular DNA topoisomerases’ inhibitors and has published more than 60 papers in this field. He is developing basic and translational research programs to identify alternative therapies for the treatment of castration-resistant prostate cancers.

Dr. Rodriguez’s research interest was focused on new therapeutic strategies in cancer treatment. He studied Biochemistry from the University of Basque Country (1992 – 1997) and obtained his PhD (1998 - 2002) in the Spanish National Research Council (IIB-CSIC). He was a junior scientist at the Department of R&D at Pharmamar Inc. (2003 - 2004), and at University of California Los Angeles (UCLA) (2005-2008). In 2009, he joined DKFZ (German Cancer Research Center) in the division “Systems Biology of Signal Transduction”, as a project manager for LungSys consortium (2009-2015). Currently, he is employed by German Center for Lung Research (DZL), in the multidisciplinary group of Lung Carcinoma.

Dr. Schmidt studies focus on clustering of molecular partners in defined subcellular compartments (signalosomes) that enable cells to exert highly specialized tasks. Current studies on the organization of signaling components within functional units and how novel pathways regulate physiological processes in cell, tissue and organ systems engage research areas of integrative pharmacology and translational medicine within a multidisciplinary approach with local, national and international collaborators. Precision cut tissue slice organ-on-a-chip techniques have been applied.

Dr. Stern received her undergraduate training in Biology from School of Sciences, University of Buenos Aires, Argentina. Her study focus in University of Buenos Aires was on molecular and evolutionary genetics. She later obtained her PhD in Cancer Biology at the University of Texas-MD Anderson Cancer Center and pursued postdoctoral training in molecular epidemiology from the National Institutes of Environmental Health Sciences, National Institutes of Health. At USC, she is currently a Professor in the departments of Preventive Medicine and Urology in the Keck School of Medicine. Dr. Stern overall research interests are in the following main areas: diet and cancer, clinical epidemiology of prostate cancer, and cancer health disparities in Latino populations.

Dr. DaLiao Xiao obtained a Ph.D. degree in Pharmacology from Loma Linda University School of Medicine, California. Dr. Xiao is an associate professor in the Center for Perinatal Biology, Loma Linda University, California, USA. Dr. Xiao’s research is mainly focusing on the fetal programming of cardiovascular system in response to in utero adverse environmental exposure. He and His research group attempt to understand the epigenetic mechanism and identify the epigenetic biomarkers during early life that have diagnostic value to predict the consequences of in utero adverse environmental exposure induced cardiovascular disease in adulthood. He has published more than 70 peer-reviewed scientific publications. His research projects are constantly supported by NIH and California State grants.

Dr. Heping Xu obtained PhD in Ophthalmology from Hunan Medical University Belfast, UK. He is currently serving as a Professor of Ocular Immunology and Director of Biological Service unit. He also has some editorial responsibilities such as Editorial Board Member of Macrophage, Editorial Board Member of Scientific Reports and Editorial Board Member of World Journal of Stem Cells. He has contributed his publications in different international journals. His research interest is in Immunopathogenesis of age-related macular degeneration, Inflammation in diabetic retinopathy, and Intraocular drug delivery.

JF Yang received the Med Ph.D. degree in Anesthesiology from Xiangya School of Medicine, Central South University (CSU), Hunan, PR China, in 2004. She is now working as the Chairman and Professor, Department of Anesthesiology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan, PR China, from 2017 to present (Division of Anesthesiology Department, Pain Ward, OR and PACU). She is the Chairman of the Perioperative Management Committee and the Association of Anesthesia and Analgesia for Cancer Patients, Hunan, PR China. She is also the Principal Investigator of many funded projects such as the National Natural Science Foundation of China Found and the High-class projects for foreign professor Found. She was a recipient of the Hunan Excellent Scientific and Technical Workers in 2016 and the Hunan Special Allowance in 2018. She is mainly engaged in the research of hepatic ischemia-reperfusion injury, perioperative medical management, tumor prognosis, cancer pain and its mechanism.

Dr. Cheng-Chia Yu is a professor of Institute of Oral Sciences, College of Oral Medicine at the Chung Shan Medical University in Taiwan. Dr. Yu obtained his Ph.D. degree and completed the postdoctoral training at the Institute of Oral Biology, School of Dentistry, National Yang-Ming University in Taiwan. He serves as visiting professor at Harvard Medical School & Brigham; Women’s Hospital from 2018- 2019. Research in his laboratory mainly focuses on the therapeutic development on targeting oral cancer stem cells and oral submucous fibrosis. He also serves as an Academic Editor or Editorial Board member for other scientific journals, such as Frontiers in Oncology, J Clin Med., Nutrients, ‎Int J Mol Sci, PLOS ONE, and Int J Dent. His remarkable work has attained Ministry of Science and Technology Special Outstanding Talent Award since 2002 in Taiwan.

Dr. Andrey A. Zamyatnin Jr. is currently a Professor, Head of the Institute of Molecular Medicine in Sechenov First Moscow State Medical University, Moscow Russia. He earned his PhD in Virology and later DSc in Virology and Molecular Biology in Lomonosov Moscow State University. His current research interests are molecular markers, molecular targets, development of immunotherapy and enzymatic therapy approaches. Additionally his research interests include programmed cell death, RNAi, virus-host interactions. His scientific publications include more than 50 articles in peer-reviewed journals. Dr. Zamyatnin acts as an Expert in several scientific funds.

Dr. Naiming Zhou received his doctoral degree in molecular biology from Zhejiang Agricultural University in 1993. His postdoctoral work was done at KU Leuven, Belgium, and at Thomas Jefferson University, Philadelphia, respectively. In 2002, he joined Incyte Corporation, Delaware, where he was involved in drug discovery projects. Afterward, he returned to the Zhejiang University where he has been appointed Professor of Biochemistry and Molecular Biology in 2006. Dr. Zhou has published more than 60 peer reviewed SCI papers and awarded 5 patents.

Dr. Naiming Zhou received his doctoral degree in molecular biology from Zhejiang Agricultural University in 1993. His postdoctoral work was done at KU Leuven, Belgium, and at Thomas Jefferson University, Philadelphia, respectively. In 2002, he joined Incyte Corporation, Delaware, where he was involved in drug discovery projects. Afterward, he returned to the Zhejiang University where he has been appointed Professor of Biochemistry and Molecular Biology in 2006. Dr. Zhou has published more than 60 peer reviewed SCI papers and awarded 5 patents.

Dr Ashok K Datusalia obtained his PhD in Pharmacology and Toxicology from NIPER S.A.S. Nagar INDIA. Currently, he serves as Assistant Professor in the Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, INDIA. Dr Ashok is author and co- author of many peer-reviewed articles in the area of diabetes, drug discovery, neuropharmacology and neurological disorders, including Alzheimer’s disease PTSD and depression.

Dr. Weiguo Huang is currently an Associate professor at Cancer Research Institute of Hengyang medical college, University of South China. He received his MD (2004) degrees in Pathology and Pathophysiology from the University of South China, Hengyang, and PhD (2010) degrees in Pathology and Pathophysiology from the Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha. His major focus is on clinical pathology, genomics, proteomics, molecular biology and bioinformatics. His current research interests are Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma.

Dr. Ravinder has done his MS (Pharm.) and Ph.D. in Pharmacology and Toxicology from NIPER-SAS nagar, India. He received his postdoctoral training at Yale School of Medicine, USA and Icahn School of medicine at Mount Sinai, NY. Dr. Ravinder has made an outstanding contribution in the field of pharmacological research and has elucidated the involvement of various pathogenic pathways like oxidative stress, PARP overactivation, inflammation and apoptosis in cerebral ischemic-reperfusion injury and diabetic neuropathy. Gene regulation is another of his interest and he has developed various tools/methods to study the mechanisms of epigenetic memory. His work is published in journals of high repute and is highly cited. He is reviewer and editorial boardmember of several international journals.

Dr. Sabbir Khan has done his MS (Pharm.) and Ph.D. in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India. Currently, he is doing his postdoctoral fellowship in cancer biology in The University of Texas, MD Anderson Cancer Center, Houston, USA. Dr. Khan has made an outstanding contribution in the field of pharmacological research and has elucidated the role of histone deacetylases (HDACs) epigenetics in the pathophysiology of diabetes and fibrotic disorders. Stem cell biology in cancer research is another of his interest. His work has been recognized at a national and international platform with several awards. He is serving as a scientific reviewer and board member for several international journals.

Abhilash Samykutty, Ph.D., is a Research Fellow at the Stephenson School of Biomedical Engineering at the Oklahoma University, Norman, OK, USA. Dr. Samykutty is an expert in Nanotechnology, Biochemistry, Immunology, and Imaging. His current research focuses on the development of cancer-targeted nanovehicles for the delivery of either contrast agent or anticancer drugs for early detection as well as a treatment against gastrointestinal cancers.

Dr. Neeraj Mishra is working as a Professor in Amity Institute of Pharmacy, Gwalior from July, 2019. He worked as a professor in pharmaceutics at ISF College of Pharmacy, Moga from June 2012 to May 2019. He has completed his B. Pharm (2000), M. Pharm (2003) and Ph.D. (2011) in Pharmaceutical Sciences from Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, Sagar (M.P.). He was qualified in National Level Test GATE conducted by IIT, Kanpur in 2001. He is having more than Sixteen years teaching/ research experience at post graduate. He is working as a brand ambassador of Bentham Science, USA. He has supervised more than 30 M Pharm students. He is having 48 International and 24 National Publication typically in recent concept of novel drug delivery system, particularly in vaccine delivery and drug targeting. He has also written 5 books chapter in national and International publisher (Nova Science Publishers).

Dr Jesus Alberto Olivares-Reyes received his PhD in Biochemistry from the National Autonomous University of Mexico, School of Chemistry, Mexico in 1997. He did his Postdoctoral training in Mechanisms of Signal Transduction in 1997-2002 from the National Institutes of Health, Bethesda, MD, USA. Currently, he is the Head of the Department of Biochemistry, CINVESTAV, Mexico and a Full Professor, (CINVESTAV-3C), Department of Biochemistry, CINVESTAV, Mexico. He has published more than 30 scientific papers in well-reputed journals. Besides, due to his outstanding contributions, he has won several awards in his research field. Also, he has been an editorial board member of the Frontiers in Vascular Physiology since 2010.

Dr. Fotios Sampsonas is currently working as a Locum Consultant of Respiratory Medicine in Patras University Hospital (with clinical and academic commitments). Presently, he is awarded a Scholarship from the Hellenic Respiratory Society that further supports the clinical service and his academic commitments. Previously, he worked as a Clinical Lecturer of Respiratory Medicine in Galway University Hospitals. He is actively involved in teaching medical students respiratory and general internal medicine. Dr. Sampsonas has around 34 Medline Publications to his credit.

Suowen Xu, Ph.D., is a natural product pharmacologist. Dr. Xu received his Ph.D. did postdoc studies in biochemistry at NHLBI/NIH, followed by a second postdoc in vascular biology at University of Rochester. Currently, Dr. Xu is Research Assistant Professor of Medicine at University of Rochester. He is a principal investigator interested in identifying novel therapeutic targets and molecular interventions of cardiovascular diseases. He was also an adjunct faculty member (Associate Professor) in the School of Pharmacy, The University of Queensland. He is an editorial board member of 4 journals and serves as reviewers for over 50 journals.

Dr. Serkan Yilmaz is serving as Professor, in Ankara University Faculty of Health Sciences.He did his Ph.D in Genetics from Gazi University, Turkey. He is an official member of a number of international societies. He received awards from The Scientific and Technological Research Council of Turkey, Gazi University and Ankara University. His research interests are genetics, toxicology, genetic diseases, pharmacology, toxicology and Molecular biology.